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From telling to sharing to silence:  
A longitudinal ethnography on the dynamics of healthcare professional-
patient communication about oral chemotherapeutic treatment for 
colorectal cancer 
 
ABSTRACT 
 
Background: Healthcare professionals are encouraged to promote concordance, a shared 
agreement about prescription and administration of medications, in their communication with 
patients.  However, there is a paucity of research regarding the impact of communication 
about self-administered oral chemotherapy.  The aim of this study was to examine the 
changing dynamics of communication through the patient journey from diagnosis of 
colorectal cancer to post treatment of chemotherapy. 
 
Methods: Over 60 hours of observational data were digitally recorded from interactions 
between 15 healthcare professionals, 8 patients with colorectal cancer prescribed 
Capecitabine and 11 family members over a six-month period in outpatient departments 
within one hospital in the United Kingdom.  Sixteen semi-structured interviews were 
conducted with patients during and after their treatment. Three focus-groups were carried out 
with healthcare professionals.  These data were analysed using thematic analysis. 
 
Results: The patient journey followed a path of four distinct phases: autocracy, physiological 
concordance, holistic concordance and silence.  Initially, communication was medicalised 
with patients occupying a passive role.  As patients continued their journey, they took a more 
active role in their treatment discussion by leading consultations and sharing their priorities 
of care.  At the end of treatment, patients felt isolated and unsupported when they were 
discharged from their oncology team. 
 
Conclusions: Communication about oral chemotherapy is not a static process; it evolves to 
take account of changing clinical requirements and growing patient confidence in dealing 
with their cancer. Different stages in the treatment journey indicate the need for different 
approaches to communication.  
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1| BACKGROUND 
 
Cancer is one of the leading causes of morbidity and mortality with more than 15 million new 
diagnoses each year1.   Colorectal cancer is the third most common form of cancer and its 
global burden is expected to increase by 60% to more than 2.2 million new cases and 1.1 
million deaths by 20302.  Presently, the most common ways to treat colorectal cancer are 
surgery, radiotherapy, targeted therapy, chemotherapy or a combination of these3.  Over the 
past decade, administration of chemotherapy has changed with a growing number of patients 
now receiving their chemotherapy in the form of oral medication that can be swallowed as 
opposed to traditional intravenous prescription4.  For example, 5-fluorouracil can now be 
administered as the oral medication Capecitabine for treatment of colorectal cancer5.  A 
recent Cochrane review highlighted no differences in overall survival rates of colorectal 
cancer patients who received oral chemotherapy versus intravenous treatment6.  As a result, 
there is a greater focus on people self-managing their chemotherapy due to concerns about 
patient safety issues in terms of self-administration and reporting of side effects.  
 
Healthcare professionals are encouraged to promote shared decision-making, mutual 
understanding about expectations of treatment and equitable communication with patients in 
effort to enhance medication-taking practices of patients7 8 9.  Research has shown that mutual 
consideration of these aspects results in better treatment outcomes in the form of increased 
patient satisfaction, a higher likelihood of patient involvement in the consultation process, 
improvement in patient knowledge about their treatment and prognosis, more effective 
medication-taking practice from patients’ and enhanced medication adherence 9 10 11 12 13 14 15 
16.  These aspects are important component of the concept known as concordance. 
 
A number of studies have examined the impact of communication on patient medication-
taking practices but limited empirical studies have focused on people living with cancer who 
administer their own oral chemotherapeutic treatments in the community 17 18.  Current 
research about oral chemotherapy medication-taking practice has tended to focus on 
adherence to the regimen and subsequent implications for patients 19 20 21 22 23 with limited 
consideration on the role of concordance between patients and healthcare professionals 24 25 26 
27 28 29.   
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Much of past research on healthcare professional-patient communication about medications 
has also involved an examination of communication at a single point in time 9 30 31.  There has 
been no known published research which has examined the changing dynamics of 
communication throughout the patient journey from early diagnosis of cancer to post-
treatment of chemotherapy.  Examining communication practices over time can uncover 
changes in the communication needs of patients during their treatment journey. 
 
This paper seeks to address these gaps in the literature by using a longitudinal methodology 
to examine the specific experiences of communication for patients taking oral chemotherapy 
and by considering to what extent concordance is important during consultations.  
 
2| METHODS 
 
A longitudinal ethnography was undertaken using diverse data collection methods including 
non-participant observations, documentation analysis, interviews and focus groups.   
Ethnography enabled the research team to build familiarity and rapport with participants, to 
examine comprehensively the communication processes between individuals, and to follow 
patients and families over a prolonged time.  The methodology enabled immersion in 
participants’ lives and facilitated understandings about the complexities of their social 
interactions.  Ethnography was chosen by the research team because its central ethos is 
concerned with observation of cultural practices; in this case, how health professionals and 
patients interacted with each other about oral chemotherapeutic treatment.  We examined the 
processes of communication between healthcare professionals, patients and family members 
in managing the oral chemotherapeutic medication Capecitabine.  This study was funded by 
the Department of Employment and Learning in Northern Ireland. 
 
2.1| Ethics 
This study was reviewed and approved by the Office of Research and Ethics Committee, 
Northern Ireland, June 2013 (Reference: 13/NI/0056), and by the Research Governance 
office of the relevant Health and Social Care Trust, June 2013 (Reference: 12144SP-SS).   
 
2.2| Context and Consent  
The study took place in in an oncology outpatient unit, in a large university teaching hospital 
in Northern Ireland.  All patient participants consented to collection of observational data 
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during their consultations with their oncologists and to participate in two semi-structured 
interviews about their experiences mid-treatment and post-treatment.  Consent was also 
obtained from family members who attended treatment appointments.  All healthcare 
professionals involved in the observed healthcare consultations received a comprehensive 
face-to-face presentation and detailed information sheet. Written consent was provided by 15 
healthcare professionals prior to commencement of the study. This process enabled the 
research team to audio-record communication between healthcare professionals and patients.  
In addition, the healthcare professionals who participated in focus groups, which included 
doctors and nurses, provided written consent to be involved in focus-groups.  Information 
about context, consent and data collection processes are illustrated in supplemental appendix 
1.  
 
2.3| Patient Recruitment and Sampling 
Participants were recruited from persons diagnosed with colorectal cancer and prescribed 
capecitabine tablets.  We chose colorectal cancer for this investigation as it is a cancer for 
which oral chemotherapy is already well established 5.  Supplemental appendix 2 notes the 
inclusion and exclusion criteria of participating patients. 
 
Ten eligible patients received initial information about this study through their oncologists.   
Nine patients went on to receive information about the study from the research team, and 
eight patients agreed to take part and provided written consent to be part of this research 
study.  Patient participants administered their own treatment away from the hospital setting 
for a period of six months.  The capecitabine regimen comprised eight cycles and consisted of 
two doses of capecitabine per day for a period of two weeks with the third week being 
reserved as a medication-free period.  Each patient participant visited an oncologist at the end 
of each three-week cycle for review.  
 
2.4| Data Collection 
We carried out observational data collection at five different time-points in the patient 
journey.  These occurred during the first (day 1), second (day 21), third (day 42), sixth (day 
126) and final eighth appointment (day 168) for each of our patient participants.  These points 
of data collection were informed by an external expert steering group made up of oncologists, 
oncology nurses and people living with cancer.  Data collection consisted of 40 separate 
observations totalling approximately 50 hours, examination of 19 information leaflets given 
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to patients, 16 semi-structured interviews with patients in receipt of capecitabine (at around 
day 60 and day 200) and three focus groups with pertinent health professionals (including 
oncologists and nurses).  Participants included eight people receiving capecitabine, eleven 
family members, nine oncologists and six nurses.  A greater number of healthcare 
professionals were recruited to this study, compared to patients, because patients interacted 
with multiple healthcare professionals.  This study took place from October 2013 to June 
2016.  Patient characteristics are described in Supplemental appendix 3. 
 
2.5| Data Analysis 
Observations and interviews were recorded by a digital audio recorder.  These data were 
transcribed verbatim by the research team (GM, SP & EM).  Field notes comprising 
observational data were also written up by the observer within 24 hours of each period of data 
collection (GM).  All these data were analysed using the process of thematic analysis which 
included familiarisation with data, generating initial codes, searching for themes, reviewing 
themes, defining themes and producing the report (GM, SP & EM) 32. 
 
2.6| Trustworthiness 
To enhance the trustworthiness of data we followed the four criteria of credibility, 
transferability, dependability and confirmability 33.  Participants were provided with their 
interview or observation transcripts as a check of the data that were collected.  Field notes 
were maintained about the research setting and comprehensive record-keeping was 
undertaken throughout the research process.  Regular team meetings ensured an appropriate 
audit trail was followed and reflexivity was addressed using a reflective diary that was 
updated after each episode of data collection.  Reflexivity involved discussion between the 
research team (GM, SP & EM) about how their interests or biases could impact their 
collection and interpretation of the data. 
 
3| RESULTS 
Following thematic analysis, we found four themes related to the patient journey throughout 
their treatment.  These were autocracy, physiological concordance, holistic concordance and 
silence. 
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3.1| Autocratic Communication Processes 
Data collection began at the first chemotherapy outpatient appointment when participants met 
the oncology physician and oncology nurse.  During this first encounter, communication was 
almost entirely led by healthcare professionals who concentrated on medical aspects of 
treatment such as how to administer capecitabine safely, how to recognise side-effects and 
when to contact a 24-hour chemotherapy help-line.  A typical example follows in this 
excerpt. 
 
Doctor 2: So, you will have 24 weeks of the tablets, delivered in 8 cycles, each lasting 3 
weeks.  The 3 weeks will consist of 14 days on and 7 off.  You will take your tablets twice, 
once in the morning thirty minutes after breakfast and once in the evening thirty minutes after 
dinner 
 
Gerry: Right, Ok. 
 
While patients appeared passive and spoke infrequently during their first appointment, they 
were highly satisfied about this style of communication.  Patients perceived that healthcare 
professionals provided them with the knowledge to competently self-administer capecitabine.  
The following excerpt demonstrates how Carol was confident about what she should do if she 
experienced side-effects.  
 
Researcher (GM): So, what happens if you get any of these side-effects? 
Carol: You must let them know and they will advise you if it is good or bad or send you to 
your doctor or come in because they have all the treatments here.  She said if you didn’t ring 
them in time, you know it makes matters worse for them and their treatment and you might 
need your tablets reduced or something like that.  
 
While patients reported high levels of satisfaction, healthcare professionals were more 
neutral.  Healthcare professionals acknowledged that patients had to receive a large amount 
of information about their regimen and it was important the information was understood.  
During focus-groups, participants suggested that information about chemotherapy could often 
appear scripted, with healthcare professionals working their way through a list of side-effects.  
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Doctor 4: I suppose it does sound a bit like a script.  We as doctors…it is the same for the 
nurses too…have a great deal of things to get across to the patient, you know?  I don’t think 
there is really another way to do it. 
 
3.2| Physiological Concordance 
This theme presents findings from patient participant consultations from appointment two 
until the fourth or fifth appointment, a period of approximately three to four months.  In these 
consultations, it was more common for patients to lead communication about their 
experiences on chemotherapy by, for example, opening communication with healthcare 
professionals, asking questions and bringing conversations back to their own life.  During this 
stage, healthcare professionals and patients collectively prioritised physiological and 
biomedical aspects of treatment in their shared communication, as illustrated by Estelle’s 
third outpatient appointment.  
 
Estelle: That is the thing I am dreading – going away on holiday and having sickness and not 
enjoying myself! 
Doctor: Well we will be giving you more chemo…or…more anti-sickness home with you but 
if you are sick, despite them or if you have problems about keeping food down – that is one of 
the things you can ring and ask us about or get someone to ring for you.   
 
During this period, family members of patients were also encouraged to share communication 
with healthcare professionals during consultations by asking questions about treatment.  This 
is evident in the following excerpt between Debbie, daughter of patient Dot, and the 
oncologist. 
 
Debbie: But then when you read that leaflet that you give us with that stuff [medication for 
nausea and vomiting], it says to take it regularly [Doctor interrupts] 
Doctor: Yes regularly.   
Debbie: With your chemotherapy tablets…we didn’t know. 
Doctor: Yeah…it is kind of working out really what is the best thing [dose] for you because 
for some people the queasiness won’t be an issue at all and therefore we would say you 
probably would not need to take the anti-sickness tablets at all – but it depends on the person. 
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The first semi-structured interviews with patients and their family members took place 
between appointments three and four.  Patients and their family members expressed 
satisfaction with the communication they received from the healthcare team up until this 
point.  Patients highlighted that communication principally focused on establishing if they 
had side-effects, how serious these were and whether combative treatment (such as 
loperamide for diarrhoea, antiemetic medication for nausea, analgesia for pain or steroidal 
topical creams for erythema) or dose reduction was the most appropriate course of action. 
 
During these consultations our field notes illuminated the importance of non-verbal 
communication between the healthcare professional team, patients and their family.  Through 
our observations, we considered that good non-verbal communication was an important 
facilitator for shared communication.  Excerpts from our diary fieldnotes on the importance 
of non-verbal communication are shown in supplemental appendix 4. 
 
3.3| Holistic Concordance 
This theme presents findings from patient participant consultations from around appointment 
five onwards, which was about months four to six of the patient journey.  In addition to 
comprising biomedical aspects, this theme demonstrated how patients and families 
communicated about psychosocial issues of chemotherapy management.  This dialogue took 
the form of expressing sadness, uncertainty and anger about living with cancer, sexual 
dysfunction, hair-loss and adjustments required for going back to work in the future.  During 
her 7th appointment, Dot expressed fear about losing her hair because of her 
chemotherapeutic treatment.  Despite nearing the end of her treatment regimen, the oncology 
nurse validated these concerns by offering psychosocial support and practical advice. 
 
Dot: I am just anxious about my hair…and maybe going bald. 
Nurse: Now sometimes, it will thin a wee bit, no-one else would notice only you: a couple of 
wee hairs on your brush or pillow.  But even if that happens and you are unhappy with that 
we can get you a wig which is almost exactly the way your hair is…so don’t worry and if you 
want a wig at any stage or you are concerned about that we can organise that anyway. 
 
This theme was representative across seven patient participants.  Only one participant, Gerry, 
did not appear to move away from physiological concordance during his treatment journey.  
Gerry was different from other patients in this study because he was the only participant who 
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did not have a family member come with him to his appointments.  Gerry stated that this was 
because he did not want to be a burden to his family, who he did not tell about his cancer or 
treatment until after chemotherapy concluded. 
 
3.4| Silence 
The final theme related to patients’ feelings once their treatment concluded.  During this 
period patients felt isolated and unsupported at the end of their treatment.  This was because 
once patient participants completed their treatment, they were no longer required to see their 
oncology team every three weeks and instead they would be followed up in six months to a 
year later.  Therefore, there was not any opportunity to communicate post-treatment anxieties 
to an oncology team.  In the excerpt that follows, Amanda highlighted how the absence of 
communication left her uncertain. 
 
Amanda: I suppose the only negative thing is, while I don’t want to be running up and down 
to the hospital, you are sort of sitting at home thinking – “is everything ok?” or “is it not 
ok?” I took a bug last week and I was thinking is this just a normal bug or is there something 
else wrong – that kind of thing because the symptoms are very, very similar to what I had 
before without the pain…so…I am trying to work out what is good for me to eat and what is 
not good for me to eat.  I know doctors can’t say because every patient is different…it’s just I 
feel I need to go to a GP (General Practitioner) and ask to see a dietician or something.  I 
feel a bit lost in that area afterwards.  But I know they can’t keep having you come down as 
well. 
 
These experiences were echoed by all eight patients in their final semi-structured interview, 
around six weeks after the final consultation.  
 
4| DISCUSSION 
Current guidelines on communication about medications are often under-pinned by the 
concept of concordance 6 9 28.  Recommendations for clinicians highlight the importance of 
collaborative communication, shared decision-making and an equal power dynamic 6 28 29.  
This study illustrates that such recommendations, while commendable, do not consider the 
developing dynamic of communication needs over time.  Communication is not a static 
process; it evolves to take account of changing clinical requirements and growing patient 
confidence in dealing with their condition. 
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In this study, in the early stage following cancer diagnosis, the central goal of consultations 
with healthcare professionals was to educate patients and their family about the practicalities 
of oral chemotherapy.  Patients and their families spoke highly of the competence of their 
oncology team at this stage of their journey.  Furthermore, and perhaps unexpectedly, was 
finding that managing side-effects was often the only priority of consultations for the patient, 
their family and healthcare professionals.  For all participants, the biological needs of patients 
tended to supersede psychological, social and spiritual needs.  This tendency is not reflected 
in both the chronic disease and oncology literature, which emphasises the importance of 
holistic care at all stages of the treatment journey 7 8 9 24 25.  
  
As patients became more familiar with their treatment regimen, they began to take greater 
control of their consultations.  Initially, this control manifested as an increased focus on the 
physiological side-effects that the patient was experiencing and how these could be medically 
managed.  Communication from healthcare professionals was subsequently directed on the 
physical impact of chemotherapy and side-effects, such as diarrhoea, nausea, vomiting, and 
erythema, and the ways in which these side-effects were managed by pharmacological 
interventions.  There was less consideration by all concerned on psychological or social 
concerns during this stage of the journey.  These forms of medicalised communication have 
traditionally been widely critiqued within medical literature 34 35.  Despite these critiques, 
patients and their family members frequently commended their attending healthcare 
professionals in relation to their communication.  Furthermore patients clearly declared a 
willingness to focus their own communication on their medical needs in the early stages.     
 
Towards the end of their journey, patients were facilitated to discuss their experiences of 
taking chemotherapy in the context of their own life through topics like; managing hair loss, 
going on family holidays, attending social events, returning to work and managing fatigue.  
Healthcare professionals supported patients to talk about their unique psychological and 
social experiences in the context of their treatment.  This finding highlights the benefit of 
holistic communication and is reflective of current oncology research 36 37 38 39. 
 
At the end of treatment, patients felt they faced an uncertain future because regular 
communication with their healthcare professional team had come to an end.  This feeling of 
uncertainty is reflected in the National Cancer Survivorship Initiative’s published report 
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where it states that 47.3% of survivors expressed fear of their cancer recurring and 19% of 
colorectal cancer survivors reported difficulty with their bowel function following recovery 
40.  The study results suggest that the fear regarding cancer recurrence is a common 
experience which may intensified by the absence of regularly scheduled oncology 
communication. 
 
4.1| IMPLICATIONS  
Most patients expressed high level of satisfaction throughout the entirety of their treatment 
journey.  In addition, patients consistently stated that they were able to adhere to their 
regimen, maintain safety and report any side-effects in a timely manner.  In contrast to the 
literature that suggests the need for holistic concordance from the outset, the study findings 
lead to the conclusion that different stages in the treatment journey indicate the need for 
different approaches to communication. Specifically, patients initially require a firm 
foundation of practical knowledge in order to become competent in the management of their 
oral chemotherapeutic regimen before they are in a position to engage in equal 
communication with their attending healthcare professionals.   
A key problem in communication identified in the study was its cessation following the 
completion of treatment. Rather than feeling confident in continuing their journey without 
regular medical input, patients felt isolated, worried and unsure.  The almost complete 
transfer of autonomy to them at this stage through the reduction of professional input was not 
therapeutically beneficial. This reduced input indicates a need to reconsider the level of 
communication and support that patients receive following completion of chemotherapy 
treatment. 
To our knowledge, this research represents the first longitudinal investigation of 
communication about capecitabine or any other oral chemotherapeutic agent.  Further 
research should examine the dynamics of communication on more complex oral 
chemotherapeutic regimens for conditions other than colorectal cancer.  Research on the 
changing dynamics of communication throughout the patient journey will support healthcare 
professionals in understanding the priorities, for their patient groups, when communicating 
about oral chemotherapy. 
 
4.2| LIMITATIONS 
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This study focused on people diagnosed with colorectal cancer who were prescribed 
Capecitabine at one oncology unit in the United Kingdom.  Therefore, transferability of these 
findings to other settings, cancer types or oral chemotherapeutic regimens may be limited.  A 
further limitation, inherent in all ethnographic research, relates to the Hawthorne effect and 
observer bias.  As reported, the research team followed best practice to reduce the impact of 
these limitations.  The research study had a low proportion of male patients (n=2) compared 
to female patients (n=6).  Because of this gender imbalance, it was more difficult to make 
comparisons to communication processes and the journey that men and women experienced.  
Finally, the voice of the pharmacist was not captured in this study because pharmacists did 
not have routine involvement with patients.   
  
5| CONCLUSION 
The recent emphasis on the importance of concordance is to be welcomed. However, much of 
the current literature does not reflect the nuances and complexities of communication 
involved in the administration of oral chemotherapy.  This study has shed light on these 
dynamic complexities, and has demonstrated the appropriateness of evolving modes of 
communication, involving the gradual enrichment of discourse from a point where factual 
information about the physical aspects of the therapy is imparted unidirectionally, through the 
stage where these aspects are discussed equally, to the point where social and psychological 
issues are added to topics of discussion. It also points to the need for communication between 
patients and professionals to continue beyond the stage of active treatment. 
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